Cannabis and migraine: the endocannabinoid system and headache

Migraine is more than a severe headache

Migraine is a complex neurological disorder. An attack can involve throbbing pain, often on one side of the head, nausea, vomiting and sensitivity to light, sound or smells. Some people experience an aura, including visual or sensory disturbances. Attacks can last for hours or days, affecting work and daily life. Understanding this complexity matters when evaluating potential treatments, including cannabinoids.

What happens in the brain during an attack?

Migraine is no longer explained simply as the widening of blood vessels. Researchers study networks in the brain and the trigeminal system. One important signaling molecule is CGRP (calcitonin gene-related peptide). This is why several established migraine treatments target CGRP or its receptor. The endocannabinoid system also interacts with nerve signaling, pain pathways, nausea and stress responses, creating a plausible biological reason to investigate cannabinoids. A plausible mechanism, however, is not proof of clinical benefit.

Why observational reports were not enough

For years, much of the evidence consisted of surveys or observations of people who already used cannabis. Many reported fewer headaches or less nausea. Such reports are important for generating research questions, but they cannot establish cause and effect. Participants who felt no benefit might have discontinued use; medicines taken at the same time, placebo responses and natural fluctuations in migraine frequency may also explain improvement. Randomized, blinded studies are needed to separate these effects.

A controlled study of acute migraine

A double-blind, randomized, placebo-controlled crossover trial published in Headache in 2026 enrolled 92 participants; 73 treated at least one attack, for a total of 247 treated migraine attacks. Participants used vaporized products containing approximately 6% THC, 11% CBD, their combination, or placebo cannabis without the active constituents. The study tested treatment of an attack already in progress, not daily prevention. After two hours, pain relief was reported for 67.2% of attacks treated with combined THC and CBD, versus 46.6% with placebo. Freedom from pain occurred in 34.5%, compared with 15.5% on placebo. The combination also showed an advantage in resolution of the most bothersome symptom, with some effects extending to 24 hours. These findings are promising but specific to the tested product, dose and route.

THC alone, CBD alone, and the limits of the result

THC alone performed better than placebo on pain relief but did not establish clear superiority on every major endpoint, including complete freedom from pain at two hours. CBD alone did not significantly outperform placebo on the primary efficacy measures. These outcomes challenge the assumption that any CBD product is automatically an effective migraine treatment. One study of 92 people, however well designed, cannot settle questions about other products or long-term results.

Acute treatment is not prevention

A medicine that helps during an acute attack is different from a medicine that prevents attacks over months. The trial does not establish whether daily cannabis reduces migraine frequency, whether oil or capsules reproduce the results, or which THC:CBD ratio is most suitable. Those questions require separate, preferably larger trials. Existing migraine-specific preventive therapies also need to be considered rather than assumed ineffective.

Could frequent use make headaches worse?

An observational study found an association between cannabis use in people with chronic migraine to medication-overuse headache. This association does not prove that cannabis caused the problem, but it is a reason to monitor frequent use and headache patterns rather than automatically increase the dose. Another consideration is cannabinoid hyperemesis syndrome (CHS): prolonged, particularly heavy cannabis use can paradoxically produce recurrent severe nausea and vomiting in some people.

Relief must be weighed against functioning and safety

In the controlled migraine study, THC-containing products could produce intoxication. Pain relief is less useful if a person cannot drive safely, concentrate or work. Vaporization under research conditions is also not identical to smoking, and inhalation itself has health considerations. The choice of route, onset of action, possible adverse effects and responsibilities after dosing all matter.

What the evidence means today

Cannabis for migraine has moved beyond anecdote: a controlled trial supports a specific inhaled THC/CBD combination for some measures of acute attack relief. Yet reproducibility, the safest formulation, long-term use and preventive effectiveness remain open questions. It is scientifically more accurate to say that cannabinoid-based treatment is being investigated than to claim cannabis has been established as a general migraine cure.

Scientific sources

1. Schuster NM, et al. Vaporized Cannabis versus Placebo for Acute Migraine: randomized double-blind placebo-controlled crossover trial. Headache. 2026.
   Find this source ↗
2. Medical Cannabis for the Treatment of Migraine in Adults: Review of the Evidence.
   Find this source ↗
3. Cannabinoids in headache: helpful or harmful? 2025.
   Find this source ↗
4. Medication overuse headache in patients with chronic migraine using cannabis.
   Find this source ↗